The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USAAbstract: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohamedtaki A Tejani, Roger B Cohen, Ranee Mehra
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/70d54dfad4194a2bac2be550248a15c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70d54dfad4194a2bac2be550248a15c1
record_format	dspace
spelling	oai:doaj.org-article:70d54dfad4194a2bac2be550248a15c12021-12-02T02:01:06ZThe contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer1177-54751177-5491https://doaj.org/article/70d54dfad4194a2bac2be550248a15c12010-06-01T00:00:00Zhttp://www.dovepress.com/the-contribution-of-cetuximab-in-the-treatment-of-recurrent-andor-meta-a4666https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USAAbstract: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone. These positive results have had a significant impact on the standard of care for advanced HNSCC. In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.Keywords: cetuximab, squamous cell carcinoma of the head and neck, epidermal growth factor receptor Mohamedtaki A TejaniRoger B CohenRanee MehraDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 173-185 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Mohamedtaki A Tejani Roger B Cohen Ranee Mehra The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
description	Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USAAbstract: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone. These positive results have had a significant impact on the standard of care for advanced HNSCC. In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.Keywords: cetuximab, squamous cell carcinoma of the head and neck, epidermal growth factor receptor
format	article
author	Mohamedtaki A Tejani Roger B Cohen Ranee Mehra
author_facet	Mohamedtaki A Tejani Roger B Cohen Ranee Mehra
author_sort	Mohamedtaki A Tejani
title	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
title_short	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
title_full	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
title_fullStr	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
title_full_unstemmed	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
title_sort	contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/70d54dfad4194a2bac2be550248a15c1
work_keys_str_mv	AT mohamedtakiatejani thecontributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer AT rogerbcohen thecontributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer AT raneemehra thecontributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer AT mohamedtakiatejani contributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer AT rogerbcohen contributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer AT raneemehra contributionofcetuximabinthetreatmentofrecurrentandormetastaticheadandneckcancer
_version_	1718402783001968640

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Ejemplares similares